TD Cowen Maintains Hold on Theravance Biopharma, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 59.6%

Neg 0% Neu 0% Pos 59.6%

TD Cowen analyst Marc Frahm maintains Theravance Biopharma (NASDAQ:TBPH) with a Hold and raises the price target from $13 to $15.